bluebird bio Inc (BLUE) Shares Bought by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. increased its holdings in shares of bluebird bio Inc (NASDAQ:BLUE) by 2.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 54,760 shares of the biotechnology company’s stock after purchasing an additional 1,415 shares during the period. Tocqueville Asset Management L.P.’s holdings in bluebird bio were worth $7,995,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CIBC Asset Management Inc raised its holdings in bluebird bio by 28.5% in the 2nd quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 395 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in bluebird bio by 9.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,320 shares of the biotechnology company’s stock valued at $922,000 after acquiring an additional 530 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in bluebird bio by 43.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 615 shares in the last quarter. Aperio Group LLC raised its holdings in bluebird bio by 9.7% in the 2nd quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock valued at $1,145,000 after acquiring an additional 646 shares in the last quarter. Finally, Stratos Wealth Partners LTD. acquired a new position in bluebird bio in the 3rd quarter valued at approximately $106,000.

BLUE has been the subject of several recent research reports. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “sell” rating in a report on Wednesday, September 5th. ValuEngine raised bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Oppenheimer reaffirmed a “hold” rating on shares of bluebird bio in a report on Tuesday, November 27th. William Blair reaffirmed a “buy” rating on shares of bluebird bio in a report on Tuesday. Finally, Piper Jaffray Companies cut bluebird bio from an “overweight” rating to a “neutral” rating and cut their price target for the company from $240.00 to $120.00 in a report on Thursday. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seventeen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $194.80.

In related news, Director James Mandell sold 1,000 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $150.77, for a total transaction of $150,770.00. Following the sale, the director now directly owns 1,568 shares in the company, valued at approximately $236,407.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider David Davidson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $139.32, for a total value of $696,600.00. Following the sale, the insider now owns 29,905 shares in the company, valued at $4,166,364.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,490 shares of company stock worth $2,901,186. Corporate insiders own 3.00% of the company’s stock.

BLUE stock opened at $102.23 on Friday. bluebird bio Inc has a 1-year low of $100.99 and a 1-year high of $236.17. The company has a market capitalization of $5.95 billion, a PE ratio of -13.26 and a beta of 2.37.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share for the quarter, beating the consensus estimate of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The company had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period in the prior year, the company posted ($1.73) EPS. The company’s revenue was up 49.2% compared to the same quarter last year. On average, sell-side analysts predict that bluebird bio Inc will post -10.71 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/12/08/bluebird-bio-inc-blue-shares-bought-by-tocqueville-asset-management-l-p.html.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: Find a Trading Strategy That Works

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply